Clinical Trials Browser

Phase 2 × Non-squamous Non-small Cell Lung Cancer × Platinum × Clear all

NCT05394233 2022-05-27

Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC

Phase 2 Unknown

Non-squamous Non-small Cell Lung Cancer